JP7838187B2 - Ｆａｐｉを合成するための中間体およびその調製方法と使用 - Google Patents

Ｆａｐｉを合成するための中間体およびその調製方法と使用

Info

Publication number
JP7838187B2
JP7838187B2 JP2025522077A JP2025522077A JP7838187B2 JP 7838187 B2 JP7838187 B2 JP 7838187B2 JP 2025522077 A JP2025522077 A JP 2025522077A JP 2025522077 A JP2025522077 A JP 2025522077A JP 7838187 B2 JP7838187 B2 JP 7838187B2
Authority
JP
Japan
Prior art keywords
compound
amino
acid
added
stirring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2025522077A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025534068A5 (https=
JP2025534068A (ja
Inventor
暁明 呉
相玉 王
田 何
清宝 楊
琳 成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yantai Lannacheng Biotechnology Co Ltd
Original Assignee
Yantai Lannacheng Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yantai Lannacheng Biotechnology Co Ltd filed Critical Yantai Lannacheng Biotechnology Co Ltd
Publication of JP2025534068A publication Critical patent/JP2025534068A/ja
Publication of JP2025534068A5 publication Critical patent/JP2025534068A5/ja
Application granted granted Critical
Publication of JP7838187B2 publication Critical patent/JP7838187B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2025522077A 2023-02-16 2024-02-15 Ｆａｐｉを合成するための中間体およびその調製方法と使用 Active JP7838187B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202310124318.XA CN115838393B (zh) 2023-02-16 2023-02-16 用于fapi合成的中间体及其制备方法和应用
CN202310124318.X 2023-02-16
PCT/CN2024/077215 WO2024169973A1 (zh) 2023-02-16 2024-02-15 用于fapi合成的中间体及其制备方法和应用

Publications (3)

Publication Number Publication Date
JP2025534068A JP2025534068A (ja) 2025-10-09
JP2025534068A5 JP2025534068A5 (https=) 2026-03-06
JP7838187B2 true JP7838187B2 (ja) 2026-03-31

Family

ID=85579761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025522077A Active JP7838187B2 (ja) 2023-02-16 2024-02-15 Ｆａｐｉを合成するための中間体およびその調製方法と使用

Country Status (8)

Country Link
US (1) US20250382329A1 (https=)
EP (1) EP4585607A4 (https=)
JP (1) JP7838187B2 (https=)
KR (1) KR20250022067A (https=)
CN (1) CN115838393B (https=)
CA (1) CA3255143A1 (https=)
TW (1) TWI871182B (https=)
WO (1) WO2024169973A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115838393B (zh) * 2023-02-16 2023-05-05 烟台蓝纳成生物技术有限公司 用于fapi合成的中间体及其制备方法和应用
WO2025091141A1 (zh) * 2023-10-30 2025-05-08 烟台蓝纳成生物技术有限公司 用放射性标记的截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂治疗甲状腺癌的方法
CN118754875B (zh) * 2024-09-06 2024-12-13 烟台蓝纳成生物技术有限公司 一种fapi前体化合物的制备工艺及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113582975A (zh) 2021-07-03 2021-11-02 上海蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
CN113621021A (zh) 2021-08-10 2021-11-09 上海蓝纳成生物技术有限公司 一种靶向成纤维细胞活化蛋白的治疗药物及其制备方法
WO2022170732A1 (zh) 2021-02-10 2022-08-18 上海蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10696631B2 (en) * 2016-05-09 2020-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
EP3749663A1 (en) * 2018-02-06 2020-12-16 Universität Heidelberg Fap inhibitor
CN109485642A (zh) * 2018-11-21 2019-03-19 希施生物科技（上海）有限公司 一种制备伊文氏蓝衍生物的方法
EP4126053A4 (en) * 2020-03-24 2024-11-20 Trustees Of Tufts College IMAGING AGENTS AND RADIOPHARMACEUTICALS TARGETING FAP, AND USES THEREOF
CN114369084B (zh) * 2021-02-10 2023-02-03 烟台蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
CN113004371A (zh) * 2021-03-01 2021-06-22 上海蓝纳成生物技术有限公司 一种长循环半衰期的前列腺特异性膜抗原靶向化合物及其制备方法和应用
CN113603678A (zh) * 2021-08-10 2021-11-05 上海蓝纳成生物技术有限公司 一种靶向成纤维细胞活化蛋白的诊断药物及其制备方法
CN115677829A (zh) * 2022-10-19 2023-02-03 广州华复生物科技有限公司 一种糖基化靶向fap化合物、靶向fap标记配合物及其制备方法与应用
CN115838393B (zh) * 2023-02-16 2023-05-05 烟台蓝纳成生物技术有限公司 用于fapi合成的中间体及其制备方法和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022170732A1 (zh) 2021-02-10 2022-08-18 上海蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
CN113582975A (zh) 2021-07-03 2021-11-02 上海蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
CN113621021A (zh) 2021-08-10 2021-11-09 上海蓝纳成生物技术有限公司 一种靶向成纤维细胞活化蛋白的治疗药物及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Theranostics，2022年，Vol.12(1)，p.422-433，Supplementary materials

Also Published As

Publication number Publication date
WO2024169973A1 (zh) 2024-08-22
TW202434565A (zh) 2024-09-01
EP4585607A4 (en) 2026-03-25
CA3255143A1 (en) 2025-03-28
US20250382329A1 (en) 2025-12-18
EP4585607A1 (en) 2025-07-16
CN115838393B (zh) 2023-05-05
JP2025534068A (ja) 2025-10-09
TWI871182B (zh) 2025-01-21
CN115838393A (zh) 2023-03-24
KR20250022067A (ko) 2025-02-14

Similar Documents

Publication Publication Date Title
JP7838187B2 (ja) Ｆａｐｉを合成するための中間体およびその調製方法と使用
JP6092513B2 (ja) フルオレン化合物
CN108727468B (zh) 环肽、包含其的医药或化妆品组成物及其制备方法
CN114409890A (zh) 一种氨基功能化的聚乙二醇衍生物及其制备方法
WO2026016269A1 (zh) 一种用于主动靶向表皮生长因子受体检测的近红外荧光探针及其制备方法与应用
JP2025534068A5 (https=)
JP7278775B2 (ja) 長鎖化合物の製造方法
RU2846888C2 (ru) Промежуточное соединение для синтеза fapi, способ его получения и применение
JP2008308690A (ja) ポリ（エチレングリコール）機能性誘導体およびその製造方法
CN114315957B (zh) 一种多肽的制备方法
CN114478424B (zh) 一种环烯基在β位取代的吖内酯衍生物的制备方法
CN1113067C (zh) 新活性肽及其制备
CN107365352A (zh) 一种新型含9‑腺嘌呤丙氨酸的三肽化合物及其制备方法和应用
TWI910785B (zh) 一種連接子-藥物的製備方法
CN116003306B (zh) 一种马来酰亚胺基己酸-PEGn类似物的linker化合物的合成方法
CN119059990B (zh) 1-氨基甲酸叔丁酯哌嗪的制备方法
CN113024521B (zh) 一种制备恩曲替尼的方法
WO2026050970A1 (zh) 一种用于吡咯并[2，3-d]嘧啶衍生物的制备方法和新颖中间体
KR20260057472A (ko) 링커-약물 제조 방법
CN116606233A (zh) 一种s-三苯甲基-l-半胱氨酰胺的制备方法
CN120309618A (zh) 吡咯并[2,1-f][1,2,4]三嗪-4(3H)-酮的合成方法
CN121800673A (zh) 氨基酸类化合物及其制备方法和应用
TW202517662A (zh) 肽醇之固相簡便合成方法
CN117964685A (zh) 抗体药物偶联物及其中间体、制备方法、应用
WO2026044709A1 (zh) 一种双官能团酰胺的制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250416

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20260225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260318

R150 Certificate of patent or registration of utility model

Ref document number: 7838187

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150